It sure seems Ginger is loving afrezza and has a platform to share her experience. She also needs to provide full disclosure so she includes the "caveats" from the label.
Now if we want to talk about caveats and make afrezza look good lets talk about Mounjarno
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
• Tirzepatide causes thyroid C-cell tumors in rats. It is
unknown whether MOUNJARO causes thyroid C-cell
tumors, including medullary thyroid carcinoma (MTC), in
humans as the human relevance of tirzepatide-induced
rodent thyroid C-cell tumors has not been determined (5.1,
13.1).
• MOUNJARO is contraindicated in patients with a personal
or family history of MTC or in patients with Multiple
Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel
patients regarding the potential risk of MTC and symptoms
of thyroid tumors (4, 5.1)
Pancreatitis: Has been reported in clinical trials. Discontinue
promptly if pancreatitis is suspected. (5.2)
• Hypoglycemia with Concomitant Use of Insulin Secretagogues or
Insulin: Concomitant use with an insulin secretagogue or insulin
may increase the risk of hypoglycemia, including severe
hypoglycemia. Reducing dose of insulin secretagogue or insulin
may be necessary. (5.3)
• Hypersensitivity Reactions: Hypersensitivity reactions have been
reported. Discontinue MOUNJARO if suspected. (5.4)
• Acute Kidney Injury: Monitor renal function in patients with renal
impairment reporting severe adverse gastrointestinal reactions.
(5.5)
• Severe Gastrointestinal Disease: Use may be associated with
gastrointestinal adverse reactions, sometimes severe. Has not
been studied in patients with severe gastrointestinal disease and is
not recommended in these patients. (5.6)
• Diabetic Retinopathy Complications in Patients with a History of
Diabetic Retinopathy: Has not been studied in patients with nonproliferative diabetic retinopathy requiring acute therapy,
proliferative diabetic retinopathy, or diabetic macular edema.
Monitor patients with a history of diabetic retinopathy for
progression. (5.7)
• Acute Gallbladder Disease: Has occurred in clinical trials. If
cholelithiasis is suspected, gallbladder studies and clinical followup are indicated. (5.8)
